Prima Mente

The AI Biology Company

[Prima Mente @PrimaMente]

Excited to be working closely with Dr @JemeenSreed and @KingsCollegeLon on this effort.

Huge thank you to @Challenge_Works, @trisdyson, @ADFoundationUK, @MNDoddie5, @FightMND, @lifearc1, @AnswerALS, @10kbrains, @packardcenter at @JohnsHopkins and @nesta_uk.

[Prima Mente @PrimaMente]

Thrilled to share that we are one of the 20 Discovery Award winners of the @longitude_prize on ALS.

With this award, we gain access to the largest and most comprehensive ALS patient datasets ever assembled, supplemented by our own internal data generation efforts.

By combining whole genome sequencing, multi-omic patient data, and high-throughput cellular models, we are bringing together a highly vetted ALS data corpus with a level of scale and quality that has not previously existed in one place.

[Prima Mente @PrimaMente]

At Prima Mente, we believe that combining clinically informed patient data, frontier biological models, and experimental validation can unlock biological insights and therapeutic opportunities that were previously out of reach.
Paired with lab autonomy, this enables us to validate insights from models at scale and accelerate discovery toward patient impact.

[Prima Mente @PrimaMente]

full press release here: https://t.co/IXDyYSdOq2

[Prima Mente @PrimaMente]

Excited to share that Prima Mente is part of the founding portfolio of the @UKSovereignAI Fund.

We are one of the first companies selected to receive backing and access to the UK’s leading AI supercomputers.

Thank you for backing AI companies building in Britain Joséphine Kant, @KanishkaNarayan, Andrew Crawford and the entire @UKSovereignAI team.

[Ravi Solanki @ravi_sola]

At @PrimaMente we are firm believers in the role of AI in the discovery of novel biology and mechanisms that underly neurological disease. Here's a great write-up by @nytimes on our work with @GoodfireAI leveraging mech interp for biological foundation models for Alzheimer's

[Prima Mente @PrimaMente]

Thank you for your continued trust, @nebiusai & @nvidia. Excited to keep pushing forward together.

[Nebius @nebiusai]

@PrimaMente is building an epigenetic foundation model for earlier detection of neurodegenerative diseases like Alzheimer’s and Parkinson’s.

CEO Ravi Solanki shares how Nebius delivers the elastic, cost-efficient HPC they need to train and scale on @NVIDIA-powered clusters.

Watch the video below👇

#HealthcareAI #AlzheimersDetection #ParkinsonsDetection

[Prima Mente @PrimaMente]

@NVIDIADC 🫱🏽‍🫲🏻 @PrimaMente🫱🏽‍🫲🏻@nebiusai

[Prima Mente @PrimaMente]

Our epigenetic foundation model, Pleiades, enables early detection of Alzheimer’s and Parkinson’s from blood, reaching 0.89 accuracy, and 0.97 when combined with protein tests. (1/6)

[Prima Mente @PrimaMente]

+ @NVIDIADC

[Prima Mente @PrimaMente]

Our epigenetic foundation model, Pleiades, enables early detection of Alzheimer’s and Parkinson’s from blood, reaching 0.89 accuracy, and 0.97 when combined with protein tests. (1/6)

[Prima Mente @PrimaMente]

Full technical blog → https://t.co/gCZ7eQUaaL (6/6)

[Prima Mente @PrimaMente]

At @PrimaMente, we build biological foundation models for discovery. Combining scale of compute, autonomy in the wet lab, and interpretability, we are tackling the gravest of human diseases. (5/5)

[Prima Mente @PrimaMente]

We used mechanistic interpretability to identify a novel class of biomarkers for Alzheimer’s detection. (1/5)

[Prima Mente @PrimaMente]

This work shows how interpretability can move models beyond black-box prediction toward biological insight and biomarker discovery.
This work is a joint effort by @GoodfireAI and @PrimaMente, read the full research post here: https://t.co/sbQdTMocLA (4/5)